- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03659071
Hematopoietic Stem Cell Transplantation and Childhood Leukemia Quality of Life in SIbling DONors (SIDONY)
Hematopoietic Stem Cell Transplantation and Childhood Leukemia: Quality of Life in SIbling DONors, Years After the Donation
The childhood cancer experience necessarily impacts the entire family. In this context, particular attention should be paid to the donor siblings of hematopoietic stem cells in the context of treatment of leukemia by grafting.
The results of the little existing work on the long-term fate of stem cell donor siblings of cancer survivors report psychosocial consequences, particularly for real post-traumatic stress in distant siblings.
Few studies have explored the medium and long-term impact of the disease, as well as donation, on a broader set of domains structuring the quality of life, through validated quantitative tools.
In France, since 2004, the LEA program (Leukemia of the Child and Adolescent) aims to assess the determinants of the state of health and quality of life in the medium and long term, patients treated for acute childhood leukemia after 1980.
The main objective of this study is to evaluate, at a distance from the transplant, the quality of life of donors from the siblings of survivors of acute childhood leukemia who received a hematopoietic stem cell transplant compared with non-donor siblings.
The SIDONY ancillary study will be proposed to families of LEA patients who have received a geno-identical sibling haematopoietic stem cell transplant (population of interest) and to families whose LEA patient has not been treated by sibling transplantation. geno-identical but still declaring to have siblings (main comparator group). Each family will be contacted by mail and the management of inclusions will be managed by the Epidemiology and Health Economics Department of AP-HM (Marseille).
Information not routinely available in the LEA database will be collected from the siblings (self-questionnaire, in addition, for each surviving child included in the cohort, data are available: sociodemographic; characteristics of the initial disease and therapeutic received; physical sequelae; quality of life.
The population meeting the inclusion criteria represents 2639 subjects: 337 donors and 2302 non-donors, making it possible to obtain high powers for analyzes (linear regression, multilevel analyzes, etc.). This study could identify profiles of siblings for whom the quality of life seems particularly impaired, potential object of individual interventions (remediation ...).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The childhood cancer experience necessarily impacts the entire family. In this context, particular attention should be paid to the donor siblings of hematopoietic stem cells in the context of treatment of leukemia by grafting.
The results of the little existing work on the long-term fate of stem cell donor siblings of cancer survivors report psychosocial consequences, particularly for real post-traumatic stress in distant siblings. disease. Few studies have explored the medium and long-term impact of the disease, as well as donation, on a broader set of domains structuring the quality of life, through validated quantitative tools.
In France, since 2004, the LEA program (Leukemia of the Child and Adolescent) aims to assess the determinants (medical, socio-economic, behavioral and environmental) of the state of health and quality of life in the medium and long term, patients treated for acute childhood leukemia after 1980. To document the quality of life of their self-reported hematopoietic stem cell donor siblings and their perception of the impact that experience of cancer in the family has had on their medium and long-term future, the organization of the LEA program can easily be extended to the establishment of an ancillary study.
objectives The main objective of this study is to evaluate, at a distance from the transplant, the quality of life of donors from the siblings of survivors of acute childhood leukemia who received a hematopoietic stem cell transplant compared with non-donor siblings.
The secondary objectives are: (a) to compare the quality of life of siblings with that of the general population; (b) to compare the quality of life of the siblings with that of the surviving patients; (c) to identify the determinants (demographic, socioeconomic, family and history of cancer) of the medium-long-term quality of life of this family; (d) remotely evaluate the donation's use of the donor sire care system as a tracer of the impact of the donation; (e) remotely evaluate the gift of the social integration of the donor sibship, particularly in terms of schooling.
The SIDONY ancillary study will be proposed to families of LEA patients who have received a geno-identical sibling haematopoietic stem cell transplant (population of interest) and to families whose LEA patient has not been treated by sibling transplantation. geno-identical but still declaring to have siblings (main comparator group). Each family will be contacted by mail and the management of inclusions will be managed by the Epidemiology and Health Economics Department of AP-HM (Marseille).
Information not routinely available in the LEA database will be collected from the siblings (self-questionnaire, to be returned by post): sociodemographic and socio-economic data relating to the siblings and the family; data concerning the quality of life of the siblings; psycho-behavioral and cognitive data; data on the state of health of the siblings; social inclusion data; recourse to the health care system. In addition, for each surviving child included in the cohort, data are available: sociodemographic; characteristics of the initial disease and therapeutic received; physical sequelae; quality of life.
Feasibility and practical impact The population meeting the inclusion criteria represents 2639 subjects: 337 donors and 2302 non-donors, making it possible to obtain high powers for analyzes (linear regression, multilevel analyzes, etc.). This study could identify profiles of siblings for whom the quality of life seems particularly impaired, potential object of individual interventions (remediation ...).
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: JULIE BERBIS, MD
- Phone Number: +33 491366.025
- Email: Julie.BERBIS@ap-hm.fr
Study Locations
-
-
Paca
-
Marseille, Paca, France, 13354
- Assistance Publique Des Hopitaux de Marseille
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
experimental group familly:
- child included in the LEA cohort
- having received allogeneic treatment of geno-identical sibling haematopoietic stem cells
Criteria for the inclusion of siblings (experimental group)
- be the brother (or sister) donor of hematopoietic stem cells
- currently at least 8 years old
- give consent to participate in the study
- be allowed to participate in the study by his parents or legal representatives
Control group familly
- child included in the LEA cohort
- who did not benefit from allogeneic hematopoietic stem cell transplantation of geno-identical siblings
- and declaring having a sibling
Criteria for the inclusion of siblings (control group)
- currently at least 8 years old
- to be the closest brother (or sister) in the LEA patient's age (in the case of multiple siblings)
- give consent to participate in the study
- be allowed to participate in the study by his parents or legal representatives In order to respect the balance within the family, a questionnaire may be distributed to other brothers and sisters who claim it.
Exclusion Criteria:
not to be allowed to participate in the study by his parents or legal representatives
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DONORS
donors from the siblings of survivors of acute childhood leukemia who have received hematopoietic stem cell transplantation questionnaire VSP-A will be performed
|
VSP-A (écu et Santé Perçue de l'Adolescent et de l'enfant): Lived and perceived health of the adolescent and child developed from the exclusive point of view of the child, for which reference values in French population are available.
The self-questionnaire used is a questionnaire developed and validated in French for children and adolescents, according to the standards in force, apprehending 9 dimensions (vitality, psychological well-being, relations with friends, leisure, family relations, good physical, relationships with teachers, school work, self-esteem)
|
Other: NON DONORS
non-donor siblings.
questionnaire VSP-A will be performed
|
VSP-A (écu et Santé Perçue de l'Adolescent et de l'enfant): Lived and perceived health of the adolescent and child developed from the exclusive point of view of the child, for which reference values in French population are available.
The self-questionnaire used is a questionnaire developed and validated in French for children and adolescents, according to the standards in force, apprehending 9 dimensions (vitality, psychological well-being, relations with friends, leisure, family relations, good physical, relationships with teachers, school work, self-esteem)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of life scores
Time Frame: 1 day
|
VSPA questionnaire score Each item is rated from 1 to 5, depending on the answer:
Scores range from 0 (the worst quality of life) to 100 (the best). |
1 day
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- RCAPHM17_0169
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematopoietic/Lymphoid Cancer
-
Leland MethenyAvailableHematopoietic/Lymphoid CancerUnited States
-
ImCheck TherapeuticsRecruitingHematopoietic/Lymphoid Cancer | Solid Tumor, AdultFrance, Belgium, United States, Germany, Spain, United Kingdom
-
University of Colorado, DenverNational Cancer Institute (NCI)CompletedHematopoietic/Lymphoid CancerUnited States
-
M.D. Anderson Cancer CenterAmgenTerminatedHematopoietic/Lymphoid Cancer | Richter's TransformationUnited States
-
University of Colorado, DenverPatient-Centered Outcomes Research InstituteCompletedHematopoietic/Lymphoid CancerUnited States
-
Cancer Research UKUnknownHematopoietic/Lymphoid CancerUnited Kingdom
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)CompletedPain | Hematopoietic/Lymphoid CancerUnited States
-
University of California, San FranciscoSwim Across AmericaRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Childhood CancerUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Cancer | SurvivorshipUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid System NeoplasmUnited States
Clinical Trials on questionnaire VSP-A
-
LifeWatch Services, Inc.Completed
-
LifeWatch Services, Inc.Completed
-
LifeWatch Services, Inc.CompletedDesaturation of BloodUnited States
-
LifeWatch Services, Inc.CompletedAutomated Measurement of Vital SignsUnited States
-
Surepulse Medical LimitedUniversity Hospital Birmingham NHS Foundation TrustCompleted
-
University of British ColumbiaRecruiting
-
The University of Texas Health Science Center,...Stryker InstrumentsRecruitingMandibular FracturesUnited States
-
Assiut UniversityNot yet recruitingIBS - Irritable Bowel Syndrome
-
University College, LondonUnknownRadiotherapy | Breast Conserving Surgery | Women With Early Breast CancerUnited Kingdom
-
Universidade Estadual do Oeste do ParanáCompletedTemporomandibular Joint DisordersBrazil